Answers are grounded in this paper and cite their sources.
The eosinophilic gastrointestinal diseases (EGIDs) are chronic, immune-mediated conditions characterized clinically by GI symptoms and histologically by pathologic infiltration of the GI tract by eosinophils. The most well-studied is eosinophilic esophagitis (EoE), but non-EoE EGIDs are becoming more frequently encountered. These have traditionally been classified by the predominant location inflammation, including eosinophilic gastritis (EoG; stomach only), eosinophilic enteritis (EoN; small bowel only), and eosinophilic colitis (EoC; colon only).(1, 2) However, multiple locations can be involved (e.g. gastric and small bowel involvement), specific segments of the small bowel can be named (e.g. eosinophilic duodenitis; EoD), and efforts are underway to standardize this nomenclature. The non-EoE EGIDs are considered rare diseases, with studies of administrative databases estimating the prevalence to be approximately 3–8/100,000, or ~50,000 cases in the United States.(3) However, recent data suggest these conditions may be under diagnosed.(4) In this paper, I will review my approach to the diagnosis and management of the non-EoE EGIDs, highlighting a number of principles that can be applied in most settings.
No takes yet. Share an insight, caveat, or question.
Evan S. Dellon (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: